Shares of Cempra (CEMP) were down 12% to $3.70 in premarket trading on Tuesday. The Chapel Hill, N.C.-based company, which focuses on developing antibiotics, reported a fourth-quarter net loss of 60 cents per share, compared with a net loss of 48 cents per share in the year-ago period. Revenue was $7.95 million, compared to $5.79 million in the same period last year.
Novavax (NVAX) shares were down 9.8% to $1.47. The Gaithersburg, Md.-based vaccine company after the market close on Monday reported a fourth-quarter net loss of 21 cents a share versus a net loss of 29 cents a share a year ago. Revenue for the quarter declined 8% year-over-year to $5.4 million.
Among the other stock movers was Ionis Pharmaceuticals (IONS) , whose shares rose 4.5% to $49. The Carlsbad, Calif.-based company reported fourth-quarter GAAP net income of $25.9 million, compared with a net loss of $71.4 million in the year-ago period. Revenue was $160.3 million, compared with $51.6 million in the fourth quarter of 2015.
Meanwhile, Amarin's (AMRN) American depository receipts were up 4.1% to $3.57 after the Dublin, Ireland-based company announced its latest numbers. Amarin, which focuses on the commercialization and development of therapeutics to improve cardiovascular health, reported a fourth-quarter net loss applicable to common shareholders of $27.5 million, or basic and diluted loss per share of 10 cents. In the same period last year, it reported a net loss applicable to common shareholders of $21.9 million, or basic and diluted loss per share of 12 cents. Total revenue for the fourth quarter of 2016 was $38.7 million, up 45% year-over-year.